LIQUID PHARMACEUTICAL COMPOSITION COMPRISING ENSIFENTRINE AND GLYCOPYRROLATE

1 . A liquid pharmaceutical composition suitable for administration by inhalation comprising:

ensifentrine particles;

(ii) glycopyrrolate; and

(iii) a diluent, which diluent comprises water,

wherein:

the glycopyrrolate is dissolved in the diluent;

the concentration of glycopyrrolate is less than or equal to 5.0 mg/mL; and

the pH of the liquid pharmaceutical composition is from 3.0 to 6.0.

2 . The liquid pharmaceutical composition according to claim 1 , wherein the pH of the liquid pharmaceutical composition is from 3.5 to 5.0.

3 . The liquid pharmaceutical composition according to claim 1 , wherein the liquid pharmaceutical composition further comprises a buffer.

4 . The liquid pharmaceutical composition according to claim 1 , wherein the concentration of the buffer is from 10.0 to 40.0 mg/mL.

5 . The liquid pharmaceutical composition according to claim 1 , wherein the concentration of glycopyrrolate is from 0.01 mg/mL to 2.0 mg/mL.

6 . The liquid pharmaceutical composition according to claim 1 , wherein the weight ratio of ensifentrine:glycopyrrolate in the liquid pharmaceutical composition is from 1:5 to 200:1.

7 . The liquid pharmaceutical composition according to claim 1 , wherein the concentration of ensifentrine particles is from 0.1 to 5.0 mg/mL.

8 . The liquid pharmaceutical composition according to claim 1 , wherein the ensifentrine particles have a Dv50 of from 0.5 to 5.0 μm.

9 . The liquid pharmaceutical composition according to claim 1 , wherein the glycopyrrolate is a pharmaceutically acceptable salt of glycopyrronium.

10 . The liquid pharmaceutical composition according to claim 1 , wherein the diluent is water and the liquid pharmaceutical composition comprises at least 80% by weight of the diluent based on the total weight of the liquid pharmaceutical composition.

11 . The liquid pharmaceutical composition according to claim 1 , wherein the liquid pharmaceutical composition further comprises a tonicity adjuster.

12 . The liquid pharmaceutical composition according to claim 11 , wherein the concentration of the tonicity adjuster is greater than or equal to 1.0 mg/mL.

13 . The liquid pharmaceutical composition according to claim 1 , wherein the liquid pharmaceutical composition further comprises one or more surfactants.

14 . The liquid pharmaceutical composition according to claim 13 , wherein the total concentration of the one or more surfactants is from 0.01 to 2.0 mg/mL.

15 . The A liquid pharmaceutical composition according to claim 1 , wherein the liquid pharmaceutical composition comprises:

(i) ensifentrine particles;

(ii) glycopyrrolate;

(iii) the diluent;

(iv) a polysorbate surfactant;

(v) optionally a sorbitan alkyl ester surfactant;

(vi) a citrate buffer; and

(vii) sodium chloride.

16 . The liquid pharmaceutical composition according to of claim 1 , wherein the liquid pharmaceutical composition comprises:

(i) from 0.1 to 2.5 mg/mL ensifentrine particles;

(ii) from 0.01 mg/mL to 2.0 mg/mL glycopyrronium bromide;

(iii) water;

(iv) from 0.1 to 1.0 mg/mL polysorbate 20;

(v) optionally from 0.01 to 0.1 mg/mL sorbitan monolaurate;

(vi) from 5.0 to 15.0 mg/mL citric acid;

(vii) from 10.0 to 20.0 mg/mL trisodium citrate; and

(viii) from 5.0 to 15.0 mg/mL sodium chloride.

17 . The liquid pharmaceutical composition according to claim 1 , which liquid pharmaceutical composition is stable with respect to chemical degradation of ensifentrine and glycopyrrolate for at least 1 month when stored at a temperature of 25° C. and a relative humidity of 60%.

18 . The liquid pharmaceutical composition according to claim 1 , which liquid pharmaceutical composition is suitable for administration by a nebuliser.

19 . A nebuliser comprising a liquid pharmaceutical composition according claim 1 .

20 - 22 . (canceled)

23 . A method of treating or preventing a disease or condition selected from chronic obstructive pulmonary disease (COPD), asthma, allergic asthma, hay fever, allergic rhinitis, bronchitis, emphysema, bronchiectasis, adult respiratory distress syndrome (ARDS), steroid resistant asthma, severe asthma, paediatric asthma, cystic fibrosis, lung fibrosis, pulmonary fibrosis, interstitial lung disease, a skin disorder, atopic dermatitis, psoriasis, ocular inflammation, cerebral ischaemia, an inflammatory disease or an auto-immune disease, which method comprises administering to said subject an effective amount of a liquid pharmaceutical composition according to claim 1 .

24 . The liquid pharmaceutical composition according to claim 3 , wherein the buffer is a citrate buffer.

25 . The liquid pharmaceutical composition according to claim 4 , wherein the concentration of the buffer is from 20.0 to 30.0 mg/mL.

26 . The liquid pharmaceutical composition according to claim 5 , wherein the concentration of glycopyrrolate is from 0.02 mg/mL to 0.25 mg/mL.

27 . The liquid pharmaceutical composition according to claim 6 , wherein the weight ratio of ensifentrine:glycopyrrolate in the liquid pharmaceutical composition is from 15:1 to 120:1.

28 . The liquid pharmaceutical composition according to claim 7 , wherein the concentration of ensifentrine particles is from 0.15 to 2.5 mg/mL.

29 . The liquid pharmaceutical composition according to claim 9 , wherein the glycopyrrolate is glycopyrronium bromide or glycopyrronium chloride.

30 . The liquid pharmaceutical composition according to claim 11 , wherein the tonicity adjuster is sodium chloride.

31 . The liquid pharmaceutical composition according to claim 12 , wherein the concentration of the tonicity adjuster is from 4.0 to 20.0 mg/mL.

32 . The liquid pharmaceutical composition according to claim 31 , wherein the concentration of the tonicity adjuster is from 6.0 to 12.0 mg/mL.

33 . The liquid pharmaceutical composition according to claim 13 , wherein the one or more surfactants are selected from a polysorbate or a sorbitan alkyl ester.

34 . The liquid pharmaceutical composition according to claim 14 , wherein the total concentration of the one or more surfactants is from 0.1 to 1.0 mg/mL.